In Florida, a new genetic disease screening program allows parents of newborns to receive free whole genome sequencing at birth, putting the state at the forefront of newborn screening. The five-year pilot program, created in July via the Sunshine Genetics Act, is paid for by a mix of private and state funding, and requires parents…
A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The Food and Drug Administration said Novo Nordisk‘s TV advertisement for its newly launched Wegovy pill for obesity included “false or misleading” claims about the medicine’s abilities and benefits to…
Piotr Swat | Lightrocket | Getty Images Hims & Hers on Saturday said that it will pull its copycat weight-loss pill off the market after sparking controversy and threats of legal action earlier this week. “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry,” the telehealth…
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive…
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline,…
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant…
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that…
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Friday said it will spend more than $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity…
The US Capitol in Washington, DC, US, on Tuesday, Jan. 27, 2026. Al Drago | Bloomberg | Getty Images Health costs have emerged as the top financial anxiety for U.S. households, according to a new survey. It’s a dynamic that experts say could pose a threat to the Republican majority in Congress during this year’s…
In 2016, when Susannah Rosen was 2½ years old, her parents, Luke Rosen and Sally Jackson, noticed during bath time that something wasn’t right. When Sally prompted Susannah to playfully kick her legs in the water, she wasn’t able to. “For our first kid, if it was a bee sting, we would run into the…
